<bi-shortcode id="summary-shortcode" data-type="summary-shortcode" class="mceNonEditable" contenteditable="false">Summary List Placement</bi-shortcode><p>Hello,</p><p>Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and this week in healthcare news:</p><ul><li>We got <a href="https://www.businessinsider.com/protection-efficacy-pfizer-covid-19-vaccine-long-term-data-2021-3">good news</a> about Pfizer's shot while <a href="https://www.businessinsider.com/factory-mixup-ruins-johnson-johnson-doses-nyt-2021-3">manufacturing problems</a> may delay shipments of J&J's jab;</li><li><a href="https://www.businessinsider.com/alzheimers-disease-scientists-new-approaches-treat-2021-3">How scientists are rethinking treatments for Alzheimer's disease</a>;</li><li><a href="https://www.businessinsider.com/primary-care-competition-amazon-parsley-one-medical-crossover-forward-2021-4">Inside the race to disrupt primary care</a>.</li></ul><p>If you're new to this newsletter, <a href="http://newsletter.businessinsider.com/join/4np/newsletter.businessinsider.com/join/4np/insider-healthcare" data-analytics-module="body_link" data-analytics-post-depth="20" data-uri="2e12e8b76b1304c6cbd7ac1c8a5fa6c4">sign up here.</a> Tips, comments' Email me at <a href="mailto:lramsey@insider.com" data-analytics-module="body_link" data-analytics-post-depth="20" data-uri="1c850c3eb45f257222d8cde9c67d2a31">lramsey@insider.com</a> or tweet <a href="https://twitter.com/lydiaramsey125" data-analytics-module="body_link" data-analytics-post-depth="20" data-uri="feb993682cd68288e207c74d333b0882">@lydiaramsey125</a>. Now, let's get to it...</p><hr><p><a href="https://www.businessinsider.com/astrazeneca-coronavirus-vaccine-has-murky-future-in-us-2021-3"><img src="https://static2.businessinsider.com/image/60410aa02dc9010018355633-2317/astrazeneca.jpg" border="0" alt="astrazeneca" data-mce-source="Getty"></a></p><h3><a href="https://www.businessinsider.com/astrazeneca-coronavirus-vaccine-has-murky-future-in-us-2021-3">It'll be too late for AstraZeneca's vaccine in the US</a></h3><p>It seems like there was news about every major vaccine rolling out across the US and Europe.</p><ul><li><strong>Moderna</strong> said on Wednesday that <a href="https://www.businessinsider.com/modernas-variant-covid-19-vaccine-starts-clinical-trial-2021-3">it launched the first study testing a version of Moderna's coronavirus vaccine tailored to fight a concerning variant.</a></li><li><strong>Pfizer</strong> on Wednesday shared that <a href="https://www.businessinsider.com/pfizers-covid-19-vaccine-is-100-effective-in-12-to-15-year-olds-2021-3">its vaccine was highly effective in a trial of 12- to 15-year-olds.</a></li><li>Then on Thursday, <strong>Pfizer</strong> said that <a href="https://www.businessinsider.com/protection-efficacy-pfizer-covid-19-vaccine-long-term-data-2021-3">longer-term data show that its shot with BioNTech remains highly effective. </a></li><li>And: The New York Times reported Wednesday that <a href="https://www.businessinsider.com/factory-mixup-ruins-johnson-johnson-doses-nyt-2021-3">roughly 15 million doses of the <strong>Johnson & Johnson</strong> vaccine were ruined because of a factory mixup.</a> It's an issue that doesn't impact doses that have already been shipped and used. </li></ul><p>Then there's AstraZeneca's shot. <a href="https://www.businessinsider.com/canada-astrazeneca-vaccine-under-55-europe-blood-clot-side-effects-2021-3">Countries are still pulling back from using the vaccine while investigators take a closer look at reports of rare blood clots.</a></p><p>So far, Europe's top regulator has <a href="https://www.businessinsider.com/astrazeneca-covid-19-vaccine-no-evidence-to-stop-use-ema-2021-3">maintained that the vaccine's benefits outweigh its risks. </a></p><p>Even so, <a href="https://www.businessinsider.com/author/andrew-dunn">Andrew Dunn</a> reports, by the time AstraZeneca secures authorization here in the US, <a href="https://www.businessinsider.com/astrazeneca-coronavirus-vaccine-has-murky-future-in-us-2021-3">we might not need it</a>. </p><p>The US may instead opt to give its doses to other countries. </p><h3><a href="https://www.businessinsider.com/astrazeneca-coronavirus-vaccine-has-murky-future-in-us-2021-3">Here's why>></a></h3><h3><a href="https://www.businessinsider.com/astrazeneca-coronavirus-vaccine-has-murky-future-in-us-2021-3">AstraZeneca's COVID-19 shot will come too late for the US</a></h3><hr><h3><a href="https://www.businessinsider.com/alzheimers-disease-scientists-new-approaches-treat-2021-3"><img src="https://static6.businessinsider.com/image/605cf67d6746fb0018a73cc0-1499/alzheimers research 4x3.png" border="0" alt="alzheimers research 4x3" data-mce-source="Skye Gould/Insider"></a></h3><h3><a href="https://www.businessinsider.com/alzheimers-disease-scientists-new-approaches-treat-2021-3">What scientists are learning about Alzheimer's</a></h3><p><a href="https://www.businessinsider.com/author/allison-deangelis">Allison DeAngelis</a> this week took a look at the conversation that's evolving around Alzheimer's disease.</p><p>It's an area of drug development that's filled with failures. </p><p>Now, scientists are seeing whether more <a href="https://www.businessinsider.com/alzheimers-disease-scientists-new-approaches-treat-2021-3">targeted rather than universal approaches</a> might be the way out of a $1.1 trillion problem. </p><h3><a href="https://www.businessinsider.com/alzheimers-disease-scientists-new-approaches-treat-2021-3">Get the full story here>></a></h3><h3><a href="https://www.businessinsider.com/alzheimers-disease-scientists-new-approaches-treat-2021-3">Scientists are coming around to a surprising new understanding of Alzheimer's disease, and it could supercharge drug development for the $1.1 trillion problem</a></h3><hr><h3><a href="https://www.businessinsider.com/primary-care-competition-amazon-parsley-one-medical-crossover-forward-2021-4"><img src="https://static5.businessinsider.com/image/5c76a44226289810fb1f9205-2400/parsley1265thave044-edit-edit.jpg" border="0" alt="Parsley Health's new center in NYC's Flatiron neighborhood" data-mce-source="Courtesy Reid Rolls for Parsley Health" data-mce-caption="Parsley Health's new center in NYC's Flatiron neighborhood."></a></h3><h3><a href="https://www.businessinsider.com/primary-care-competition-amazon-parsley-one-medical-crossover-forward-2021-4">The race to disrupt primary care </a></h3><p><a href="https://www.businessinsider.com/author/shelby-livingston">Shelby Livingston</a> on Tuesday had the scoop that <a href="https://www.businessinsider.com/walmart-chief-medical-officer-dr-thomas-van-gilder-is-leaving-2021-3">a top Walmart healthcare exec, the company's chief medical officer, is leaving the retail giant.</a> </p><p><a href="https://www.businessinsider.com/walmart-chief-medical-officer-dr-thomas-van-gilder-is-leaving-2021-3">You can read the full memo on his exit that Shelby obtained</a>. </p><p>It's another departure from Walmart's healthcare leadership after <a href="https://www.businessinsider.com/sean-slovenski-departs-walmart-for-lab-testing-company-bioiq-2020-8">Sean Slovenski left last summer</a>. And it's happening after we reported in February that Walmart's slowing <a href="https://www.businessinsider.com/walmart-healthcare-strategy-health-clinics-2021-2">its ambitious health clinics push.</a></p><p>Walmart is just one of a multitude of forces trying to reshape how we get primary care in the US. </p><p>This week, Shelby and <a href="https://www.businessinsider.com/author/patricia-kelly-yeo">Patricia Kelly Yeo</a> took a look at how <a href="https://www.businessinsider.com/primary-care-competition-amazon-parsley-one-medical-crossover-forward-2021-4">four primary-care companies are holding on</a> in the increasingly competitive space. </p><h3><a href="https://www.businessinsider.com/primary-care-competition-amazon-parsley-one-medical-crossover-forward-2021-4">Find out more>></a></h3><h3><a href="https://www.businessinsider.com/primary-care-competition-amazon-parsley-one-medical-crossover-forward-2021-4">4 primary-care upstarts share how they plan to fend off Amazon Care and other telehealth giants as they vie for a slice of a $170 billion market</a></h3><hr><h3><a href="https://www.businessinsider.com/moving-to-florida-texas-lower-cost-of-living-healthcare-medicaid-2021-3"><img src="https://static3.businessinsider.com/image/6064b5aedaf0f10018f99458-1778/Moving Truck.jpg" border="0" alt="Moving Truck" data-mce-source="Carlo Allegri/Reuters" data-mce-caption="People are moving to lower cost-of-living states during the coronavirus pandemic, but some are discovering they won't be able to afford healthcare coverage."></a></h3><h3><a href="https://www.businessinsider.com/moving-to-florida-texas-lower-cost-of-living-healthcare-medicaid-2021-3">People are moving to places that haven't expanded Medicaid</a></h3><p>Hundreds of thousands of people are moving to states with lower costs of living, like Florida and Texas.</p><p>But, as <a href="https://www.businessinsider.com/author/kimberly-leonard">Kimberly Leonard</a> reports, people who once qualified for Medicaid are learning that their new states haven't expanded the program.</p><p>It's an issue that can make their healthcare more expensive. </p><h3><a href="https://www.businessinsider.com/moving-to-florida-texas-lower-cost-of-living-healthcare-medicaid-2021-3">Dig in more here>></a></h3><h3><a href="https://www.businessinsider.com/moving-to-florida-texas-lower-cost-of-living-healthcare-medicaid-2021-3">People flocked to Florida and Texas for a lower cost of living during the pandemic. Some were shocked when their healthcare got way more expensive.</a></h3><hr><p><strong>More news that kept us busy this week:</strong></p><ul><li><strong>Crossover Health</strong> on Monday said it raised $168 million. <a href="https://www.businessinsider.com/crossover-health-lays-out-its-plans-to-disrupt-the-healthcare-system-2021-3">See the presentation the key Amazon healthcare partner gave to investors about the future of its business.</a></li><li><strong>Cityblock Health</strong> raised <a href="https://www.businessinsider.com/how-cityblock-built-1-billion-business-sickest-patients-2021-1">$192 million, an extension of its Series C</a>. Tiger Global led the round, <a href="https://www.businessinsider.com/digital-health-startups-backed-by-tiger-global-management-2021-3">adding Cityblock to the list of startups the $50 billion asset manager has backed in the past five months.</a></li><li><strong>Alloy Therapeutics</strong> <a href="https://www.businessinsider.com/peter-thiel-8vc-invest-in-alloy-therapeutics-75-million-round-2021-4">raised $75 million</a>. The biotech's goal is to make $1 in profit. <a href="https://www.businessinsider.com/peter-thiel-8vc-invest-in-alloy-therapeutics-75-million-round-2021-4">Peter Thiel and 8VC think it's worth $563 million.</a></li><li>We read the 323-page financial filings <strong>23andMe</strong> released as part of its SPAC deal so you don't have to. <a href="https://www.businessinsider.com/biggest-obstacles-23andme-faces-in-going-public-s4-analysis-2021-3">Here are the 5 key challenges its business faces. </a></li><li><strong>Plus:</strong> Take a look at the life and career of <a href="https://www.businessinsider.com/23andme-ceo-anne-wojcicki-life-career-family-photos-2021-3">23andMe CEO Anne Wojcicki, who's about to be worth more than $1 billion when the genetic-testing giant makes its public debut.</a></li></ul><hr><p>- Lydia</p><p><a href="https://www.businessinsider.com/insiders-top-healthcare-stories-for-the-week-ending-april-2-2021-4#comments">Join the conversation about this story »</a></p> <p>NOW WATCH: <a href="https://www.businessinsider.com/what-its-like-travel-during-coronavirus-outbreak-planes-airports-virus-2020-3">Here's what it's like to travel during the coronavirus outbreak</a></p>
Click here to read full news..
